1. Search Result
Search Result
Results for "

Gomisin L2

" in MedChemExpress (MCE) Product Catalog:

123

Inhibitors & Agonists

3

Biochemical Assay Reagents

5

Peptides

12

Inhibitory Antibodies

44

Natural
Products

54

Recombinant Proteins

16

Isotope-Labeled Compounds

21

Antibodies

45

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N5001

    Apoptosis Cancer
    Euphorbia factor L2, a lathyrane diterpenoid isolated from caper euphorbia seed (the seeds of Euphorbia lathyris L.), has been traditionally applied to treat cancer. Euphorbia factor L2 shows potent cytotoxicity and induces apoptosis via a mitochondrial pathway .
    Euphorbia Factor L2
  • HY-128358

    Phosphodiesterase (PDE) Neurological Disease
    MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 µM .
    MR-L2
  • HY-N1529

    (±)-Gomisin M1

    HIV Infection
    Gomisin M1 ((±)-Gomisin M1) is a potent anti-HIV agent with an EC50 of <0.65 μM .
    Gomisin M1
  • HY-N3963

    (+)-Gomisin M2

    HIV Infection Neurological Disease Inflammation/Immunology Cancer
    Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra rubriflora with anti-HIV activity (EC50 of 2.4 μM). Gomisin M2 exhibits anti-cancer and anti-allergic activities and has the potential for Alzheimer’s disease research [2].
    Gomisin M2
  • HY-N6866

    Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Gomisin N, isolated from Schisandra chinensis. Gomisin N has the potential for use in the treatment of allergy. Gomisin N is an anti-cancer agent candidate capable of inhibiting the proliferation and inducing the apoptosis in cancer [2] .
    Gomisin N
  • HY-N2413

    Others Metabolic Disease
    Gomisin D, a lignan compound isolated from Fructus Schisandra, is a potential antidiabetic and anti-Alzheimer’s agent. Gomisin D inhibits UDP-Glucuronosyltransferases activity and scavenges ABTS(+) radicals. Gomisin D is used as a quality marker of Shengmai San and shenqi Jiangtang Granule .
    Gomisin D
  • HY-N8400

    Endogenous Metabolite Others
    Roridin L2, a fungal metabolite, is a biosynthetic precursor of Satratoxin G. Roridin L2 possesses little in vitro or in vivo toxic activity .
    Roridin L2
  • HY-N7485

    (-)-Gomisin K1

    Others Cancer
    Gomisin K1 ((-)-Gomisin K1) is a lignan that exhibits anti-cancer activity. Gomisin K1 inhibits HeLa cell growth, with an IC50 of 5.46 μM .
    Gomisin K1
  • HY-N0858R

    HIV Infection
    Gomisin G (Standard) is the analytical standard of Gomisin G. This product is intended for research and analytical applications.
    Gomisin G (Standard)
  • HY-N8158

    Others Others
    Gomisin S is a dibenzocyclooctadiene lignan .
    Gomisin S
  • HY-N8159

    Others Others
    Gomisin U is a lignan compound .
    Gomisin U
  • HY-N2235

    Others Inflammation/Immunology
    Gomisin O is isolated from the fruits of Schizandra chinensis .
    Gomisin O
  • HY-N0385
    Gomisin J
    3 Publications Verification

    AMPK Calcium Channel Cardiovascular Disease Metabolic Disease
    Gomisin J is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity . Gomisin J suppresses lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecules through activation of AMPK, LKB1 and Ca 2+/calmodulin-dependent protein kinase II and inhibition of fetuin-A in HepG2 cells. gomisin J has potential benefits in treating nonalcoholic fatty liver disease [2].
    Gomisin J
  • HY-N2246

    Others Inflammation/Immunology
    Gomisin H is a dibenzocyclooctadiene lignan isolated from the fruits of Schizandra chinensis BAILL .
    Gomisin H
  • HY-P9972

    PDR001

    PD-1/PD-L1 Cancer
    Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) .
    Spartalizumab
  • HY-N7958

    Others Others
    Gomisin F is a Lignans product that can be isolated from the seeds of Schisandra chinensis (Turcz.) Baill. .
    Gomisin F
  • HY-N2265

    Others Others
    Angeloyl-(+)-gomisin K3 is a dibenzocyclooctane lignan .
    Angeloyl-(+)-gomisin K3
  • HY-N7310

    Nuclear Factor of activated T Cells (NFAT) Others
    Gomisin E, a dibenzocyclooctadiene lignan isolated from the fruits of Schizandra chinensis, inhibits NFAT transcription with an IC50 of 4.73 μM [2].
    Gomisin E
  • HY-P99610

    BI-754091

    PD-1/PD-L1 Cancer
    Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
    Ezabenlimab
  • HY-P99639

    APL-501; CBT-501; GB-226

    PD-1/PD-L1 Cancer
    Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
    Geptanolimab
  • HY-N0858
    Gomisin G
    1 Publications Verification

    HIV Infection
    Gomisin G is an ethanolic extract of the stems of Kadsura interior; exhibits potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 microgram/mL and 300, respectively.
    Gomisin G
  • HY-P99345

    TSR-042

    PD-1/PD-L1 Cancer
    Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
    Dostarlimab
  • HY-101093
    CA-170
    1 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes [2].
    CA-170
  • HY-P9902A
    Pembrolizumab (anti-PD-1)
    2 Publications Verification

    MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

    PD-1/PD-L1 Cancer
    Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 [2].
    Pembrolizumab (anti-PD-1)
  • HY-N7825

    Others Cancer
    Gomisin L1 is a lignan, shows inhibitory effect on cell viability of A2780 and Ishikawa cells, with IC50s of 39.06 μM and 74.16 μM, respectively .
    Gomisin L1
  • HY-P1812
    AUNP-12
    3 Publications Verification

    NP-12

    PD-1/PD-L1 Cancer
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
    AUNP-12
  • HY-P1812A
    AUNP-12 TFA
    3 Publications Verification

    NP-12 TFA

    PD-1/PD-L1 Cancer
    AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
    AUNP-12 TFA
  • HY-N0695

    Gomisin-B; Wuweizi ester-B; Schisantherin-B

    Amyloid-β Inflammation/Immunology
    Schisantherin B (Gomisin-B; Wuweizi ester-B; Schisantherin-B) is a natural product.
    Schisantherin B
  • HY-P99052
    Tislelizumab
    2 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma [2] .
    Tislelizumab
  • HY-P99109

    GLS-010; AB-122; WBP-3055

    PD-1/PD-L1 Cancer
    Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma [2].
    Zimberelimab
  • HY-P99499

    JNJ 63723283; JNJ 3283

    PD-1/PD-L1 Interleukin Related TNF Receptor Cancer
    Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
    Cetrelimab
  • HY-P99048

    IBI308

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer [2] .
    Sintilimab
  • HY-N0692
    Schisandrol B
    2 Publications Verification

    Gomisin-A; TJN-101; Wuweizi alcohol-B

    Reactive Oxygen Species Cytochrome P450 Autophagy Cancer
    Schisandrol B (Gomisin-A) is a major active constituent of Schisandra chinensis with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and CYP3A and also has anti-inflammatory, anti-diabetic and antioxidant activities [2] .
    Schisandrol B
  • HY-P99573

    MGD-013

    LAG-3 Inflammation/Immunology Cancer
    Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity [2] .
    Tebotelimab
  • HY-16638

    PDDF

    Thymidylate Synthase Metabolic Disease
    CB 3717 is a potent inhibitor of human thymidylate synthetase, competitively binding with 5,10-methylenetetrahydrofolate (Ki = 4.9 X 10(-9) M). It also competitively inhibits human dihydrofolate reductase with dihydrofolate (Ki = 2.3 X 10(-8) M). In WI-L2 human lymphoblastoid cells, CB 3717 treatment led to a significant decrease in cellular dTTP levels and a notable increase in dUMP levels, indicating a disruption in nucleotide metabolism. The growth-inhibitory effect of CB 3717 was reversed by thymidine supplementation, demonstrating that thymidylate synthetase became rate-limiting in the presence of this compound. Delayed thymidine supplementation beyond 8 hours resulted in severe cytotoxicity, underscoring the critical timing of nucleotide rescue strategies in CB 3717-treated cells .
    CB 3717
  • HY-N0859

    Schizanhenol; Gomisin-K3

    UGT Cancer
    Schisanhenol is a natural compound solated from Schisandra rubriflora; UGT2B7 UDP-glucuronosyltransferases inhibitor.
    Schisanhenol
  • HY-N0695R

    Amyloid-β Inflammation/Immunology
    Schisantherin B (Standard) is the analytical standard of Schisantherin B. This product is intended for research and analytical applications. Schisantherin B (Gomisin-B; Wuweizi ester-B; Schisantherin-B) is a natural product.
    Schisantherin B (Standard)
  • HY-N0694
    Schisantherin A
    1 Publications Verification

    Gomisin-C; Schizantherin-A; Wuweizi ester-A

    NF-κB Inflammation/Immunology
    Schisantherin A is a dibenzocyclooctadiene lignan. Schisantherin A inhibits p65-NF-κB translocation into the nucleus by IκBα degradation.
    Schisantherin A
  • HY-128736

    Endogenous Metabolite Metabolic Disease
    L-2-Phosphoglyceric acid is an endogenous metabolite .
    L-2-Phosphoglyceric acid
  • HY-128736C

    Endogenous Metabolite Metabolic Disease
    L-2-Phosphoglyceric acid sodium hydrate is an endogenous metabolite .
    L-2-Phosphoglyceric acid sodium hydrate
  • HY-N0692R

    Reactive Oxygen Species Cytochrome P450 Autophagy Cancer
    Schisandrol B (Standard) is the analytical standard of Schisandrol B. This product is intended for research and analytical applications. Schisandrol B (Gomisin-A) is a major active constituent of Schisandra chinensis with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and CYP3A and also has anti-inflammatory, anti-diabetic and antioxidant activities [2] .
    Schisandrol B (Standard)
  • HY-148171

    HIV HBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Infection
    L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-human immunodeficiency virus (HIV) and anti-hepatitis B virus (HBV) activity .
    L-2'-Fd4C
  • HY-N3834

    Others Others
    Epipterosin L 2'-O-glucoside is a Sesquiterpenoids product that can be isolated from the rhizomes of Cibotium barometz (L.) J.Sm. .
    Epipterosin L 2'-O-glucoside
  • HY-101414

    L-2,4-Diaminobutyric acid

    GABA Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DABA (L-2,4-Diaminobutyric acid) is a week GABA transaminase inhibitor with an IC50 of larger than 500 μM; exhibits antitumor activity in vivo and in vitro.
    L-DABA
  • HY-113039

    (S)-2-Hydroxyglutaric acid

    Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite Cancer
    L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with Km and Ki of 2.52 mM and 11.13 mM, respectively [2].
    L-2-Hydroxyglutaric acid
  • HY-148200

    ADC Cytotoxin Telomerase Cancer
    L2H2-6OTD, containing one to four G-quadruplex binding loops, is a telomeric inhibitor analogue. l2H2-6OTD has telomerase inhibitory activity with an IC50 value of 15 nM .
    L2H2-6OTD
  • HY-148200A

    Telomerase Cancer
    L2H2-6OTD acetate contains one to four G-quadruplex binding loops and is a telomere inhibitor analog. L2H2-6OTD acetate has telomerase inhibitory activity with an IC50 value of 15 nM .
    L2H2-6OTD diformic
  • HY-W015114

    (S)-2-Hydroxyglutaric acid disodium

    Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite Cancer
    L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with Km and Ki of 2.52 mM and 11.13 mM, respectively [2].
    L-2-Hydroxyglutaric acid disodium
  • HY-101414A

    L-2,4-Diaminobutyric acid hydrobromide

    Endogenous Metabolite GABA Receptor Neurological Disease Cancer
    L-DABA (L-2,4-Diaminobutyric acid) hydrobromide is a week GABA transaminase inhibitor with an IC50 of larger than 500 μM; exhibits antitumor activity in vivo and in vitro.
    L-DABA hydrobromide
  • HY-48517

    Others Cancer
    L2H2-6OTD intermediate-1 is an intermediate for the synthesis of L2H2-6OTD (HY-148200) and can be used for ADC preparation. L2H2-6OTD, a telomestatin analog with telomerase inhibitory activity (IC50: 15 nM) .
    L2H2-6OTD intermediate-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: